教育背景

2017/09-至今，温州医科大学，妇产科学，博士在读，导师：朱雪琼/陈填烽

2015/09-2017/06，温州医科大学，妇产科学，硕士，导师：朱雪琼

2011/07-2015/07，温州市人民医院，妇产科，住院医师

2006/09-2011/06，温州医学院，妇产科专业，学士

科研项目

1. 浙江省医药卫生科技计划项目，2017KY485，PRDX1对宫颈癌化疗药物敏感性的影响及其相关机制的研究，2017/01-2018/12，配套3万，在研，主持；

1. 温州市科技局医疗卫生科技项目，Y20160339，Peroxiredoxins对宫颈鳞癌生物学行为影响的研究，2017/01-2018/12，自筹，在研，主持；

   
   

2. 国家自然科学基金面上项目，81671809，构建基于TRAIL-exosome的siRNA和Cisplatin共载纳米系统及治疗耐药宫颈癌的研究，2017/01-2019/12，配套58万，在研，参加；

1. 国家自然科学基金青年科学基金项目，81602305，宫颈癌中TGF-β1诱导肿瘤干细胞介导顺铂耐药的分子机制研究，2018/01-2020/12，配套17万，在研，参加；

   
   

2. 国家自然科学基金青年科学基金项目，81701828，构建基于间充质干细胞-外泌体杂交膜包覆的siRNA纳米系统及其在卵巢癌治疗中的应用，2018/01-2020/12，配套20万，在研，参加。

发表论文

1. 1. Zhou Q#, Hu X#, Zhou J, Zhao M, Zhu X, Zhu X*. Human papillomavirus DNA in surgical smoke during cervical loop electrosurgical excision procedures and its impact on the surgeon. Cancer Manag Res. 2019;11:3643-3654.

   2. 
      

   3. Hu X, Liu H, Ye M, Zhu X*. Prognostic value of microvessel density in cervical cancer. Cancer Cell Int. 2018;18:152.

   4. 
      

   5. Hu X, Li S, Zhou L, Zhao M, Zhu X*. Effect of vitamin E supplementation on uterine cervical neoplasm: A meta-analysis of case-control studies. PLoS One. 2017;12(8):e0183395.

   7. Lu e#, Hu X#, Zhu X*.Effect of peroxiredoxin 1 expression on the biological behavior of cervical cancer cells and the underlying mechanisms. Journal of cancer. 2019.

   .
   

2. 胡晓丽，盛波，朱雪琼.选择性孕酮受体调节剂在子宫肌瘤治疗中的应用研究发展.浙江医学.40(24):2714-2718.

3. 胡晓丽，朱雪琼. Hedgehog信号通路在妇科恶性肿瘤中的研究. 医学研究杂志. 2016；45(10):19-23.

   
   

   非第一作者论文：

(1)Liu Y, Song Y, Hu X, Yan L, Zhu X. Awareness of surgical smoke hazards and enhancement of surgical smoke prevention among the gynecologists. J Cancer. 2019;10(12):2788-2799.

(2)Liu Y, Song Y, Ye M, Hu X, Wang ZP, Zhu X. The emerging role of WISP proteins in tumorigenesis and cancer therapy. J Transl Med. 2019;17(1):28.

(3)Chetry M, Thapa S, Hu X, Song Y, Zhang J, Zhu H, Zhu X. The Role of Galectins in Tumor Progression, Treatment and Prognosis of Gynecological Cancers. J Cancer. 2018;9(24):4742-4755.

(4)Zhou L, Xu X, Liu H, Hu X, Zhang W, Ye M, Zhu X. Prognosis Analysis of Histone Deacetylases mRNA Expression in Ovarian Cancer Patients. J Cancer. 2018;9(23):4547-4555.

(5)Zhao C, Lu E, Hu X, Cheng H, Zhang JA, Zhu X. S100A9 regulates cisplatin chemosensitivity of squamous cervical cancer cells and related mechanism. Cancer Manag Res. 2018;10:3753-3764.

(6)Li S, Hu X, Ye M, Zhu X. The prognostic values of the peroxiredoxins family in ovarian cancer. Biosci Rep. 2018;38(5). pii: BSR20180667.

(7)Chetry M, Li S, Liu H, Hu X, Zhu X. Prognostic values of aquaporins mRNA expression in human ovarian cancer. Biosci Rep2.535. 2018 Apr 27;38(2). pii: BSR20180108.

(8)Shen Q, Hu X, Zhou L, Zou S, Sun LZ, Zhu X. Overexpressionof the 14-3-3γ protein in uterine leiomyoma cells results in growth retardation and increased apoptosis. Cell Signal. 2018;45:43-53.

(9)Zhang W, Zhang Y, Hu X, Cheng H, Hua Y, Zhu X*. Danshen extract regulates the expression of aquaporin 3 in human amniotic epithelial cells. Front Biosci (Landmark Ed). 22, 1138-1147.

(10)Zhu H, Luo H, Zhu X, Hu X, Zheng L, Zhu X*. Pyruvate kinase M2 (PKM2) expression correlates with prognosis in solid cancers: a meta-analysis. Oncotarget. 2017;8: 1628-1640.

(11)Shen Q, Ye W, Hu X, Zhao C, Zhou L, Zhu X*. The Effects of Guizhi Fuling Capsule Drug Serum on Uterine Leiomyoma Cells and Its Mechanism. Evid Based Complement Alternat Med. 2016;2016:2393640.

(12)Zhu H, Zhu X, Zheng L, Hu X, Sun L, Zhu X*. The role of the androgen receptor in ovarian cancer carcinogenesis and its clinical implications. Oncotarget. 2016 Oct 11. doi: 10.18632/oncotarget.12561. 

(13)Hua Y, Zhang W, Hu X, Yang A, Zhu X*. The use of misoprostol for cervical priming prior to hysteroscopy: a systematic review and analysis. Drug Des Devel Ther. 2016 Sep 6;10:2789-2801.

(14)Jiang W, Shen Z, Luo H, Hu X, Zhu X*. Comparison of polyvinyl alcohol and tris-acryl gelatin microsphere materials in embolization for symptomatic leiomyomas: a systematic review. Minim Invasive Ther Allied Technol. 2016,19:1-12.

(15)Zhu H, Luo H, Zhang W, Shen Z, Hu X, Zhu X. Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Des Devel Ther. 2016;10:1885-95.

(16)Zhang W, Shen Z, Luo H, Hu X, Zheng L, Zhu X*. The benefits and side effects of bevacizumab for the treatment of recurrent ovarian cancer. Curr Drug Targets. 2016.

(17)Zhu H, Luo H, Shen Z, Hu X, Sun L, Zhu X*. Transforming growth factor-β1 in carcinogenesis, progression, and therapy in cervical cancer. Tumour Biol. 2016,37(6):7075-83.

(18)Hua Y, Zhang W, Hu X, Yang A, Zhu X*. The use of misoprostol for cervical priming prior to hysteroscopy: systematic review and analysis.Drug Des Devel Ther. 2016,10:2789-2801.

获奖情况

1、2018年，浙江省医学会妇科肿瘤学分会妇科肿瘤论文比赛二等奖

2、2016年、2017年，温州医科大学学业奖学金一等奖

3、2017年，温州医科大学叶碧绿奖学金